Reuters logo
8 个月内
BRIEF-Juno Therapeutics places JCAR015 phase II rocket trial on clinical hold
2016年11月23日 / 下午1点37分 / 8 个月内

BRIEF-Juno Therapeutics places JCAR015 phase II rocket trial on clinical hold

1 分钟阅读

Nov 23 (Reuters) - Juno Therapeutics Inc :

* Juno Therapeutics Inc - clinical hold was initiated after two patients suffered cerebral edema earlier this week

* Juno - one patient died and as of tuesday night other is not expected to recover.

* Juno says company is assessing data from cases and trial and is evaluating its options regarding jcar015 program

* Juno notified FDA of voluntary hold and is working with agency and data and safety monitoring board to determine next steps

* Juno says co's trials and plans for its other CD19-directed car T cell product candidates, including JCAR017, are not affected

* Juno places JCAR015 phase II rocket trial on clinical hold Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below